
Novo Nordisk breaks ground on new $2 billion production facility in North Carolina
pharmafile | March 29, 2016 | News story | Manufacturing and Production, Research and Development | $2 billion, Clayton, Novo, Novo Nordisk, building, diabetes, nordisk, north carolina, production facility
Novo Nordisk has begun work on a new $2 billion production facility in Clayton, North Carolina, which will produce active pharmaceutical ingredients for a range of their current and future GLP-1 and insulin products.
Planned to be fully operational in 2020, the Clayton facility will ensure production capacity for diabetes care products in the US for the coming decade.
The new site is situated adjacent to their existing 42,000m2 facility which assembles and packages FlexPen and FlexTouch prefilled insulin devices for the US market. This further expansion is expected to create close to 700 new permanent jobs while up to 2,500 people will be working on the site’s construction when the project is at its peak.
Lars Rebien Sørensen, president and chief executive officer at Novo Nordisk, comments: “As the prevalence of diabetes has grown in the US, so too has the demand for effective treatments. It gives me great pride to break ground on our new facility site in Clayton where we have an existing, strong organisation. This site will play a vital role in enabling us to meet the needs of people living with diabetes in the US for years to come.”
Sean Murray
Related Content

FDA approves Wegovy for treatment of MASH in adults with liver fibrosis
The US Food and Drug Administration (FDA) has granted accelerated approval for Wegovy (semaglutide) as …

BioMed X and Novo Nordisk partner on oral peptide drug delivery innovation
BioMed X has announced a new collaboration with Novo Nordisk to improve oral delivery of …

MetP Pharma releases positive data on intranasal semaglutide administration
MetP Pharma has released new data highlighting the advantages of its MetP technology in delivering …






